Side Population in Pancreatic Ductal Adenocarcinoma (PDAC)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Baki Topal, University Hospital, Gasthuisberg
ClinicalTrials.gov Identifier:
NCT00936104
First received: July 7, 2009
Last updated: July 1, 2012
Last verified: July 2012

July 7, 2009
July 1, 2012
August 2008
July 2012   (final data collection date for primary outcome measure)
Characterization of side population (SP) cells in pancreatic ductal adenocarcinoma (PDAC) [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00936104 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Side Population in Pancreatic Ductal Adenocarcinoma (PDAC)
Prognostic and Therapeutic Relevance of the 'Side Population' in Pancreatic Cancer

In the current project we aim to study the oncological process of pancreatic cancer, from a perspective of the CSC-theory and in particular through the 'side population' (SP)-approach. The SP seems to be enriched for CSC and doesn't a priori exclude any CSC-subpopulation. After isolation from pancreatic cancer resection specimens, SP cells will be characterized by gene-expression profiling based on microarray analysis. We'll identify markers and pathways (with emphasis for stem cell and cancer -related ones) that are differentially expressed in SP versus the rest of tumour cells (the 'main population' or MP). In order to assess the prognostic relevance of the SP, we'll study these genes using the high-throughput Nanostring technology in about 200 snap-frozen PDAC resection specimens of patients from our prospective database. Finally, two monoclonal antibodies (mAB) will be tested as novel therapeutic agents in vivo (mouse model), wherein the choice of mAB will be based on prognostically relevant molecular targets and pathways obtained from the Nanostring results.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Pancreatic cancer tissue specimen

Probability Sample

SP cells will be identified through incubation with vital dye Hoechst 33342 of cell suspensions that are obtained from fresh human pancreatic cancer resection specimens.

  • Neoplasm
  • Pancreas
Not Provided
SP in PDAC
Side population cells isolated from resection specimens obtained from patients with pancreatic cancer
Van den Broeck A, Gremeaux L, Topal B, Vankelecom H. Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine. BMC Cancer. 2012 Aug 15;12:354. doi: 10.1186/1471-2407-12-354.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
July 2012
July 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Resected pancreatic ductal adenocarcinoma (PDAC)
  • Informed consent

Exclusion Criteria:

  • Age < 18years
  • Pregnancy
  • Pre-operative radiotherapy
  • Pre-operative chemotherapy
  • IPMT
Both
18 Years to 85 Years
No
Contact information is only displayed when the study is recruiting subjects
Belgium
 
NCT00936104
BT-PDAC-SP
Not Provided
Baki Topal, University Hospital, Gasthuisberg
University Hospital, Gasthuisberg
Not Provided
Not Provided
University Hospital, Gasthuisberg
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP